Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 383.14%.

  • Coherus Oncology's EBIT Margin rose 3910800.0% to 383.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.36%, marking a year-over-year increase of 1691900.0%. This contributed to the annual value of 41.83% for FY2024, which is 371600.0% up from last year.
  • Per Coherus Oncology's latest filing, its EBIT Margin stood at 383.14% for Q3 2025, which was up 3910800.0% from 443.59% recorded in Q2 2025.
  • Coherus Oncology's EBIT Margin's 5-year high stood at 17.16% during Q4 2024, with a 5-year trough of 2937.05% in Q1 2024.
  • In the last 5 years, Coherus Oncology's EBIT Margin had a median value of 134.62% in 2022 and averaged 353.2%.
  • As far as peak fluctuations go, Coherus Oncology's EBIT Margin tumbled by -27281900bps in 2024, and later soared by 23391400bps in 2025.
  • Coherus Oncology's EBIT Margin (Quarter) stood at 53.91% in 2021, then tumbled by -111bps to 113.54% in 2022, then skyrocketed by 34bps to 75.29% in 2023, then soared by 123bps to 17.16% in 2024, then plummeted by -2333bps to 383.14% in 2025.
  • Its last three reported values are 383.14% in Q3 2025, 443.59% for Q2 2025, and 597.91% during Q1 2025.